Amneal Pharmaceuticals initiated shipments of its generic version of Nasonex mometasone furoate nasal spray on April 4, 2017, the company said.
According to Amneal, the mometasone furoate nasal spray is its “first pharmaceutical product in spray form”; the company also markets a generic tobramycin inhalation solution.
Amneal Executive VP of Sales and Marketing Lim Luce commented, “This launch marks a new milestone for us. As the first nasal spray product from Amneal, it stands as yet another example of how we continue to expand into new and more complex dosage forms. Metered dose inhalers, transdermal patches and chewable tablets are just a few of those in the pipeline that we are excited to bring to market, significantly expanding our product offering.”
Read the Amneal Pharmaceuticals press release.
